Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “With the acquisition of EryDel S.p.A. in October last year, we have successfully shi
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks